Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum — CAMCAP  

Pregnancy Related Clinical Trial

Official title: Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum

Status Completed

Clinical Trial Summary

This study addresses the second aim of the grant (R01 HD0899455), which is to determine temporal changes in CYP3A4-mediated drug metabolism sequentially across pregnancy and after birth.

Clinical Trial Description

This study addresses the second aim of the grant (R01 HD0899455), which is to determine temporal changes in CYP3A4-mediated drug metabolism sequentially across pregnancy and after birth.

In studies with human hepatocytes, we found that serum from women in the first trimester led to the highest CYP3A4 expression compared to those from the second or third trimester or after birth. Among the hormones with elevated plasma concentrations in early pregnancy, our studies revealed that thyroid hormone enhances CYP3A4 expression in human hepatocytes. Based on the results, we hypothesized that CYP3A4-mediated drug metabolism is highest during early pregnancy (compared to the later time points of pregnancy or postpartum period) in part due to changes in thyroid hormone concentration.

To test this hypothesis, we will evaluate the conversion of endogenous cholesterol to its 4β-hydroxycholesterol metabolite, which is facilitated by CYP3A4. To assess additional factors that affect CYP3A activity, we will obtain DNA. About 75% of African Americans, but only 10-20% of people of European descent, carry the active allele CYP3A5*1, which significantly increases the clearance of many CYP3A4/5 substrates, including the conversion of cholesterol to 4β-hydroxycholesterol. ;

Related Conditions & MeSH terms

• Pregnancy Related

• NCT number: NCT05504889
• Study type: Observational
• Source: Northwestern University
• Status: Completed
• Start date: June 17, 2022
• Completion date: June 30, 2023